Abstract: An inhalable composition for use as a medicament in the treatment of a subject wherein said composition comprises: one or more cannabinoids or a pharmaceutically acceptable derivative or salt thereof; a propellant; a monohydric or polyhydric alcohol; and a glycol and/or glycol ether, characterised in that the ratio of monohydric or polyhydric alcohol to glycol or glycol ether by weight is from 6:1 to 1:1, wherein the composition is administered in the form of an aerosol having a fine particle fraction of 60% or more.

Abstract: An inhalable composition for use as a medicament in the treatment of a subject wherein said composition comprises: one or more cannabinoids or a pharmaceutically acceptable derivative or salt thereof; a propellant; a monohydric or polyhydric alcohol; and a glycol and/or glycol ether, characterised in that the ratio of monohydric or polyhydric alcohol to glycol or glycol ether by weight is from 6:1 to 1:1, wherein the composition is administered in the form of an aerosol having a fine particle fraction of 60% or more.

Abstract: An inhalable composition for use as a medicament in the treatment of a subject wherein said composition comprises: one or more cannabinoids or a pharmaceutically acceptable derivative or salt thereof; a propellant; a monohydric or polyhydric alcohol; and a glycol and/or glycol ether, characterised in that the ratio of monohydric or polyhydric alcohol to glycol or glycol ether by weight is from 6:1 to 1:1, wherein the composition is administered in the form of an aerosol having a fine particle fraction of 60% or more.

Abstract: An inhalable composition for use as a medicament in the treatment of a subject wherein said composition comprises: one or more cannabinoids or a pharmaceutically acceptable derivative or salt thereof; a propellant; a monohydric or polyhydric alcohol; and a glycol and/or glycol ether, characterised in that the ratio of monohydric or polyhydric alcohol to glycol or glycol ether by weight is from 6:1 to 1:1, wherein the composition is administered in the form of an aerosol having a fine particle fraction of 60% or more.

Abstract: An inhalable composition for use as a medicament in the treatment of a subject wherein said composition comprises: one or more cannabinoids or a pharmaceutically acceptable derivative or salt thereof; a propellant; a monohydric or polyhydric alcohol; and a glycol and/or glycol ether, characterized in that the ratio of monohydric or polyhydric alcohol to glycol or glycol ether by weight is from 6:1 to 1:1, wherein the composition is administered in the form of an aerosol having a fine particle fraction of 60% or more.

Abstract: The present invention provides a cannabinoid inhaler, compositions, and methods for delivering a cannabinoid composition to a subject. The cannabinoid composition is delivered in the form of inhaled droplets of respirable size via pulmonary administration. The invention may be used in the treatment of a condition or disorder selected from the group consisting of neuropathic pain, cannabis addiction, nausea, motion sickness, arthritis, and neurodegenerative disease.

Abstract: A method of assembling and testing a simulated cigarette. Assembling the simulated cigarette to have an elongate main body containing a reservoir for an inhalable composition, a breath operated valve, and a refill valve. Testing the integrity of the reservoir requires applying a pressured gas to open the refill valve to pressurise the reservoir, measuring the pressure drop in the reservoir, and providing a pass indication if the pressure drop remains below a predetermined threshold. It also requires testing the breath operated valve by applying suction at an inhaling end, measuring the flow rate from the cigarette and providing a pass indication if the flow rate falls outside a predetermined limit.

Abstract: An inhalable composition for use as a medicament in the treatment of a subject wherein said composition comprises: one or more cannabinoids or a pharmaceutically acceptable derivative or salt thereof; a propellant; a monohydric or polyhydric alcohol; and a glycol and/or glycol ether, characterized in that the ratio of monohydric or polyhydric alcohol to glycol or glycol ether by weight is from 6:1 to 1:1, wherein the composition is administered in the form of an aerosol having a fine particle fraction of 60% or more.

Abstract: The present invention provides a cannabinoid inhaler, compositions, and methods for delivering a cannabinoid composition to a subject. The cannabinoid composition is delivered in the form of inhaled droplets of respirable size via pulmonary administration. The invention may be used in the treatment of a condition or disorder selected from the group consisting of neuropathic pain, cannabis addiction, nausea, motion sickness, arthritis, and neurodegenerative disease.